Conference Coverage

Many VTE patients live in fear of the next event


 

REPORTING FROM THSNA 2018


“If you’re working with patients who believe they don’t have any control over their own care, or if they’re younger or have other disease states, or if they have difficulty getting to and from the hospital, all of those things contribute to elevated emotional harms,” Dr. Feehan said. “That level of emotional harm is clinically relevant.”

After the research team shared the study results with staff of the university’s thrombosis services, clinicians started changing how they interview patients. “For example, instead of asking just ‘Have you experienced any VTE symptoms?’ they now ask things like, ‘How are you feeling?’ or ‘How are things going for you living with the disease?’” Dr. Feehan noted. “Then, patients might say, ‘I’m actually quite worried.’ Such questions can help patients open up about how they feel and foster a better relationship with their provider. A better relationship with their provider might help them feel more in control.”

The study was supported by Pfizer Independent Grants for Learning & Change, Bristol-Myers Squibb Independent Medical Education, the Joint Commission, the National Eye Institute, and an unrestricted grant from Research to Prevent Blindness. Dr. Feehan disclosed that he has consulted for Pfizer in the past.

SOURCE: Feehan et al. THSNA 2018, Poster 75.

Pages

Recommended Reading

Beware of polypharmacy in patients taking warfarin
MDedge Hematology and Oncology
VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
MDedge Hematology and Oncology
Deaths in patients on emicizumab
MDedge Hematology and Oncology
CHMP recommends approval for generic prasugrel
MDedge Hematology and Oncology
Product approved for hemophilia patients in Japan
MDedge Hematology and Oncology
CHMP recommends rejection for betrixaban
MDedge Hematology and Oncology
EHRA releases new guide for NOAC use
MDedge Hematology and Oncology
Aspirin appears comparable to rivaroxaban for VTE
MDedge Hematology and Oncology
Clopidogrel proves noninferior to Plavix
MDedge Hematology and Oncology
Reversal agent exhibits efficacy in patients with major bleeding
MDedge Hematology and Oncology